HOW TO MANAGE THE TOXICITY AND ASSESSING THE RESPONSE IN PATIENTS WITH melanoma immunotherapy

The melanoma immunotherapy is going through a phase of great development, thanks to the important achievements in many clinical trials, starting in 2010, following the introduction of antibodies to immunological checkpoint as CTLA-4, and, in particular, PD -1. The purpose of this project is to deepen the main scenarios of melanoma difficult patient management affection for antibody therapy ant-PD-1, through examples of interactive clinical situations.